Urine

Dogs are incredible – if unlikely – allies in conservation

Retrieved on: 
Sunday, January 7, 2024

Think hunting dogs, herding dogs, police dogs or search and rescue dogs.

Key Points: 
  • Think hunting dogs, herding dogs, police dogs or search and rescue dogs.
  • But have you heard of conservation dogs?
  • Conservation dogs fall mainly into two categories: guardian dogs and sniffer dogs (also called scent, detection or detector dogs).

The nose that knows

  • The film is based on the true story of Maremma dogs, trained to protect little penguins from foxes on Middle Island near Warrnambool in southwest Victoria.
  • The penguin population had dwindled to fewer than ten before the Maremma dogs got involved.
  • They can be trained to find animals or plants, or “indirect” signs animals have left behind such as poo or feathers.


Sniffer dogs have been trained for various missions such as:
finding rare and endangered species
detecting invasive animals during eradication or containment such as fire ants or snakes
locating pest plants
supporting wildlife surveys by detecting scats (poo), urine, vomit, nests, carcasses and even diseases.
They have worked in extreme conditions on land (including on sub-Antarctic islands) and at sea, and can even detect scent located underground. Sniffer dogs have also trained to recognise individual animals such as tigers by scent.

The ultimate scent detection machine

  • A much larger proportion (seven to 40 times larger) of the dog’s brain is dedicated to decoding scent.
  • Dogs analyse the air from each of their nostrils independently, detecting tiny variations in scent concentration.
  • Besides being the ultimate scent detection machine, dogs are great ambassadors for conservation – melting hearts all the way to Hollywood.



Finding the right candidate for the job

  • Trainers use toys and play as a reward, so dogs learn to associate this reward with the target scent.
  • It’s so easy that the scent-learning part of the job is usually the quickest.
  • And if the dog had a troubled background before being rescued, rehabilitation is the most time-consuming and difficult component of the training.

What type of dog can become a sniffer dog?

  • The most important aspect of the association learning process is having the right dog – one with obsessive behaviour.
  • And any breed, sex and age of dog can present this personality type.


Read more:
Scientists find burnt, starving koalas weeks after the bushfires

Top jobs for conservation dogs


Meet dogs working in conservation around the world:
detecting orca poo
making and keeping World Heritage-listed islands and Antarctica pristine
wildlife search and rescue
working as guardians
containing fire ants
leading weed eradication on land or water
monitoring wind farms
finding vomit (rejected owl pellets, to be precise)
supporting environmental assessments
helping Tasmanian devils find mates
detecting diseases.
These are just a few of the dogs making a difference in our fight to protect biodiversity. But we have barely scratched the surface of their potential!
Romane H Cristescu works for Detection Dogs for Conservation, at the University of the Sunshine Coast. She is receiving external funding through multiple government-funded, foundation association, not-for-profit group, and research council grants. She is a founding member and current executive of the Australasian Conservation Dogs Network.

PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study

Retrieved on: 
Saturday, January 6, 2024

PanGIA Biotech , a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy.

Key Points: 
  • PanGIA Biotech , a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy.
  • This announcement comes as the company prepares to launch additional clinical studies in multi-cancer early detection using the PanGIA® Liquid Biopsy Platform.
  • In 2020, the company received IRB approval and launched a novel AI integrated urine based liquid biopsy study.
  • “Based on the high sensitivity and high specificity of the PanGIA prostate study, PanGIA Biotech is now preparing to significantly expand the platform by launching follow-on studies in ten additional cancer types,” said Tricia Schumann, Chief Investment Officer of PanGIA Biotech.

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

Retrieved on: 
Thursday, January 4, 2024

BURLINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced preliminary unaudited fourth quarter 2023 net FUROSCIX revenue in a range of $5.9 million to $6.1 million, representing sequential growth of 55% to 61% over $3.8 million net FUROSCIX revenue reported for the third quarter of 2023.

Key Points: 
  • For the full year 2023, the Company anticipates net revenue to be in a range of $13.4 million to $13.6 million.
  • The gross-to-net discount decreased to approximately 18% from launch through the end of Q4 versus 21% from launch through the end of Q3.
  • Inventory levels at the end of Q4 2023 were consistent with levels at the end of Q3 2023.
  • scPharmaceuticals will report its final and complete fourth quarter and full-year 2023 financial results in March.

HydroGraph’s Graphene Selected by Hawkeye Bio for Use in its Early-Stage Lung Cancer Detection Biosensor

Retrieved on: 
Wednesday, January 3, 2024

HydroGraph’s graphene, the third company to be certified globally by the Graphene Council, was selected by Hawkeye Bio based on the purity and consistency of its graphene.

Key Points: 
  • HydroGraph’s graphene, the third company to be certified globally by the Graphene Council, was selected by Hawkeye Bio based on the purity and consistency of its graphene.
  • The sensor also improves the patient experience by using non-invasive biological samples, such as blood, urine, saliva or exhaled breath, in early-stage lung cancer testing.
  • “Hawkeye Bio leverages HydroGraph’s pristine graphene to manufacture pharmaceutical grade biosensors for the detection of lung cancer from a standard blood draw.
  • “After several years of working together with Hawkeye, we have developed a strong partnership and are thrilled that our graphene helped bring their biosensor to market to save lives.”

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Anoro Ellipta (previously Anoro), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Laventair Ellipta (previously Laventair), umeclidinium bromide,vilanterol, Date of authorisation: 08/05/2014, Revision: 18, Status: Authorised